Extreme body mass index and survival in newly diagnosed multiple myeloma patients

Dear Editor, The majority of established prognostic factors for multiple myeloma (MM) are not modi ﬁ able and include cytogenetic abnormalities, beta-2 microglobulin, lactate dehydrogenase, age, and Eastern Cooperative Oncology Group (ECOG) performance status [1, 2]. There is a lack of evidence-based clinical interventions available to complement existing treatment modalities to improve prognostic trajectories. Obesity is a potentially modi ﬁ able well-established risk factor [3, 4] associated with an increased incidence of MM [5 – 7]. However, the evidence is less clear for the association of obesity with clinical outcomes after a new MM diagnosis. Two pooled analyses of large prospective cohorts have demonstrated a relationship between increasing BMI and mortality [8, 9], but it is unclear whether the increased mortality among patients with higher BMI is due to increased cancer incidence, decreased survival after diagnosis, or both [8, 9]. The only study to evaluate BMI at the time of MM diagnosis and long-term clinical outcomes analyzed data from 2968 patients in the Veterans Health Administration System. The authors of that study found that obese patients with MM experienced superior survival, except those with substantial weight loss in the year prior to diagnosis and those who were underweight at diagnosis (BMI < 18.5) [10]. The focus of the present study was to investigate the impact of BMI on progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed MM. We obtained the data from 1142 patients from the Multiple Myeloma Research Foundation CoMMpass registry (NCT01454297, version IA15). CoMMpass is a prospective observational study that followed patients every six months until death or censoring. BMI was calculated from height and weight recorded at MM diagnosis and classi ﬁ ed into: underweight (<18.5 kg/m 2 ), normal (18.5 – <25 kg/m 2


Dear Editor,
The majority of established prognostic factors for multiple myeloma (MM) are not modifiable and include cytogenetic abnormalities, beta-2 microglobulin, lactate dehydrogenase, age, and Eastern Cooperative Oncology Group (ECOG) performance status [1,2]. There is a lack of evidence-based clinical interventions available to complement existing treatment modalities to improve prognostic trajectories.
Obesity is a potentially modifiable well-established risk factor [3,4] associated with an increased incidence of MM [5][6][7]. However, the evidence is less clear for the association of obesity with clinical outcomes after a new MM diagnosis. Two pooled analyses of large prospective cohorts have demonstrated a relationship between increasing BMI and mortality [8,9], but it is unclear whether the increased mortality among patients with higher BMI is due to increased cancer incidence, decreased survival after diagnosis, or both [8,9]. The only study to evaluate BMI at the time of MM diagnosis and long-term clinical outcomes analyzed data from 2968 patients in the Veterans Health Administration System. The authors of that study found that obese patients with MM experienced superior survival, except those with substantial weight loss in the year prior to diagnosis and those who were underweight at diagnosis (BMI < 18.5) [10].
The focus of the present study was to investigate the impact of BMI on progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed MM. We obtained the data from 1142 patients from the Multiple Myeloma Research Foundation CoMMpass registry (NCT01454297, version IA15). CoMMpass is a prospective observational study that followed patients every six months until death or censoring.
BMI was calculated from height and weight recorded at MM diagnosis and classified into: underweight (<18.5 kg/m 2 ), normal (18.5-<25 kg/m 2 ), overweight (25-<30 kg/m 2 ), moderately obese (30-<35 kg/m 2 ) and severely obese (≥35 kg/m 2 ). Of the 1,135 patients in the CoMMpass registry, 22 were excluded from the analysis for missing data or extreme values (<36 inches). Demographic and clinical covariates were ascertained from baseline data. The Charlson Comorbidity Index (CCI) was calculated utilizing past medical history and adverse event data. A simplified frailty scale was calculated utilizing age, CCI and Eastern Cooperative Oncology Group (ECOG) performance status, and patients were divided into frail and nonfrail as described previously [11].
PFS was defined as time from diagnosis to first progression or death. Patients who did not experience an event were censored at last follow-up. OS was defined as time from diagnosis to death or last follow-up for those who survived.
A multivariable Cox regression model was used to estimate hazard ratios (HR) for the relationship between BMI and PFS, and OS. The model included age, race, sex, International Staging System (ISS), ECOG performance status, cytogenetic risk, induction treatment combination, and autologous stem cell transplantation (ASCT) as covariates. ASCT (specifically, any ASCT before the first progression event) was treated as a time-dependent covariate to adequately adjust for time at risk before receiving ASCT. CCI and frailty score was not included in the main multivariable model as the CCI score was calculated utilizing past medical history and adverse event data, the accuracy of which is dependent on the health care provider's documentation. Instead, we performed sensitivity analyses, including CCI (removing age) or frailty score (removing age and ECOG) in multivariate models.
Survival curves and median survival were estimated using the Kaplan-Meier method. All analyses were exploratory with no adjustment for multiplicity, and the alpha error level was set at 5% for presenting 95% confidence intervals (CI). Analyses were performed using R version 3.5.1.
Descriptive characteristics of 1120 patients with available BMI are provided in Table 1. Thirty percent had a normal BMI, 38.2% were overweight, 17·9% were moderately obese, 11.9% were severely obese and 2.0% were underweight. The median age at diagnosis did not vary by BMI category (63-64 years) except for the severely obese that had a median age of 61 years. Male patients were more likely to be overweight or obese (73.5%) compared to female patients (59.5%), and females were more likely to be underweight (3.6%) compared to males (0.88%). White (72.1%) and Black patients (70.1%) were more likely to have an elevated BMI compared to Asians (44.4%), other (50%), and unknown race (53.6%). The ECOG performance status was higher at the extremes of BMI; 68% of underweight patients and 58% of severely obese patients had ECOG ≥ 1 compared to 43-51% in normal weight, overweight, or moderately obese patients. In contrast, individuals were less likely to receive carfilzomib-based therapy if they had an elevated BMI (27% normal vs. 18% overweight, 11% moderately obese, 13% severely obese). There were no significant differences in CCI (p = 0.21) and frailty score between BMI groups (p = 0.4).
Underweight and severely obese patients had lower median PFS and OS than normal, overweight, and moderately obese patients. Multivariable models associating PFS and OS with BMI showed that underweight patients had a significantly higher risk of death (HR: 2.32; 95% CI: 1.09, 4.97). In addition, severely obese patients may have higher risk of progression (HR: 1.29; 95% CI: 0.99, 1.67) and death (HR: 1.43; 95% CI: 0.98-2.08) when compared to patients with normal BMI, although differences between groups did not achieve statistical significance ( In this comprehensive analysis of a prospective cohort with a median follow up of over 2 years, we found that being underweight was associated with a 132% higher risk of death from any cause. Given that age, ISS, CCI, and cytogenetic risk were not altered in underweight (vs. normal weight) patients, we speculate that the observed adverse outcomes in this subgroup maybe due to high ECOG (i.e., poor performance status) and disease-related weight loss. Additionally, being severely obese demonstrated a suggestive association with worse PFS and OS in newly diagnosed MM patients. This is biologically plausible and could reflect a worse ECOG performance status in the severely obese patients, which may render them less likely to tolerate full dose induction or transplant regimens. For example, we observed that participants in the newly diagnosed MM cohort were less likely to receive carfilzomib-based therapy if they had an elevated BMI. Another mechanism may be that of increased adipocytes in the bone marrow niche of severely obese patients. Higher BMI correlates with higher levels of bone marrow adipocytes, which in turn can provide a favorable microenvironment for MM cell growth [12], contributing to oncogenesis and MM disease progression [13]. MM cells co-cultured with adipocytes exhibit increased growth and adhesion [14].
The study in US veterans showed that overweight and obese patients had lower MM mortality compared to healthy weight patients, whereas underweight patients had higher MM mortality. This association between higher BMI and survival became nonsignificant after adjustment for weight loss in the year prior to diagnosis. Like the US Veteran cohort, we observed inferior survival among the small number of underweight patients. However, our study, which included a separate category for BMI ≥ 35 kg/m 2 , showed that severely obese patients also had a suggestion of worse prognosis compared to normal weight patients. It is notable that the MM patients in the CoMMpass registry were 61% male, whereas the veterans' cohort was 98% male. Therefore, sex differences in the association of obesity with mortality may have contributed to the observed differences [15].
A unique strength of this study was the use of a large wellcharacterized cohort with information on clinical disease characteristics and treatment regimens. Study limitations include the lack of weight measurement prior to and during the study [10] and the use of BMI instead of newer body composition assessments [16]. However, BMI is the most widely available measure in epidemiologic studies and its use allows for comparisons across studies [8,9]. We did not have data to evaluate potential confounding by weight loss prior to MM diagnosis, which has been shown to contribute to worse OS [10]. Additional limitations include the inability to evaluate differences in drug doses and treatment-emergent adverse events in relation to BMI and systematic missingness for some variables such as ECOG, which is a known issue with large multi-institutional databases.
This comprehensive examination of BMI and survival in newly diagnosed MM patients suggests that underweight and severe obesity are associated with worse survival. Future studies of weight trajectories and body composition may help clarify these observations. Additionally, clinical research to understand if patients with extreme BMI may benefit from weight management strategies to improve outcomes may be of importance.